Literature DB >> 3216971

Brachytherapy in the treatment of recurrent solitary brain metastases.

D O Heros1, D L Kasdon, M Chun.   

Abstract

Conventional therapy for solitary brain metastases includes radiotherapy and surgical resection in selected cases. Often, however, the metastasis recurs and limits the quality of life and survival of the patient. Once the metastasis recurs, therapeutic options are limited. Brachytherapy delivers a high total dose of radiation to a localized area, allowing reirradiation at the time of recurrence. Three patients with recurrent brain metastases treated with iridium-192 implants are presented; two of these patients had breast carcinoma and one had malignant melanoma. The implants allowed long term survival in the two patients with recurrent metastatic breast carcinoma. Unfortunately, the patient with melanoma did not respond to the brachytherapy and died within 7 months of implantation. The approaches to treatment to metastatic brain tumors and the rationale for using brachytherapy are discussed.

Entities:  

Mesh:

Year:  1988        PMID: 3216971     DOI: 10.1227/00006123-198812000-00008

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  3 in total

Review 1.  Brachytherapy for brain tumors.

Authors:  Todd W Vitaz; Peter C Warnke; Viviane Tabar; Philip H Gutin
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

2.  CT and MR imaging after placement of the GliaSite radiation therapy system to treat brain tumor: initial experience.

Authors:  Maria G Matheus; Mauricio Castillo; Matthew Ewend; Jeffrey K Smith; Lester Knock; Sharon Cush; David E Morris
Journal:  AJNR Am J Neuroradiol       Date:  2004-08       Impact factor: 3.825

3.  Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study.

Authors:  Michael A Mooney; Wenya Linda Bi; Jonathan M Cantalino; Kyle C Wu; Thomas C Harris; Lucas L Possatti; Parikshit Juvekar; Liangge Hsu; Ian F Dunn; Ossama Al-Mefty; Phillip M Devlin
Journal:  J Neurooncol       Date:  2019-11-19       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.